Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 15;32(2):020501.
doi: 10.11613/BM.2022.020501. Epub 2022 Apr 15.

Laboratory medicine in pandemic of COVID-19

Affiliations

Laboratory medicine in pandemic of COVID-19

Leida Tandara et al. Biochem Med (Zagreb). .

Abstract

After the outbreak in China in the year 2019, severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) quickly spread around the world causing a protracted pandemic. Approximately one-third of infections appear to be asymptomatic. Symptomatic disease is characterized primarily by symptoms of respiratory tract infection of varying severity. But Coronavirus Disease 2019 (COVID-19) is much more than an acute respiratory disease because SARS-CoV-2 affects many organs inducing a vast number of symptoms such as cardiovascular, neurological, gastrointestinal, dermatological, with numerous complications. Short and long-term effects of infection, severe ones, and especially mild forms of the disease which affect a huge number of patients need to be further investigated. Laboratory medicine has a crucial role in early diagnosis of the disease, recognition of the patients who need hospital care, and close monitoring of hospitalized patients to timely identify associated clinical complications as well as follow-up of patients with long-term COVID-19.

Keywords: COVID-19; GDF-15; Guillain-Barré syndrome; infertility; interleukin-6.

PubMed Disclaimer

Conflict of interest statement

Potential conflict of interest None declared.

Figures

Figure 1
Figure 1
Comparison of serum IL-6 concentrations between the group with the non-fatal outcome and the group with the fatal outcome by Mann-Whitney test. The median concentration of IL-6 in the group with the non-fatal outcome was 24 pg/mL (IQR 11-53) and for the group with fatal outcome was 472 pg/mL (IQR 119-2116). IL-6 – interleukin-6. SARS-CoV-2 – severe acute respiratory syndrome Coronavirus 2. IQR – interquartile range.
Figure 2
Figure 2
Comparison of serum GDF-15 concentrations between the group with the fatal outcome and the group with the non-fatal outcome by Student´s t-test. The mean ± SD concentration of GDF-15 in the group with the fatal outcome (N = 35) was 10,259 ± 4538 pg/mL and for the group with non-fatal outcome (N = 44) was 5067 ± 2980 pg/mL. GDF-15 – Growth differentiation factor 15. SARS-CoV-2 – severe acute respiratory syndrome Coronavirus 2. SD – standard deviation.

Similar articles

References

    1. Dodig S, Čepelak I, Čepelak Dodig D, Laškaj R. SARS-CoV-2 - a new challenge for laboratory medicine. Biochem Med (Zagreb). 2020;30:030503. 10.11613/BM.2020.030503 - DOI - PMC - PubMed
    1. Lippi G, Plebani M. The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks. Clin Chem Lab Med. 2020;58:1063–9. 10.1515/cclm-2020-0240 - DOI - PubMed
    1. Jin JY, Haiyan Y, Wangquan J, Weidong W, Shuaiyin C, Weiguo Z, et al. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. 2020;12:372. 10.3390/v12040372 - DOI - PMC - PubMed
    1. Baig AM. Updates on What ACS Reported: Emerging Evidences of COVID-19 with Nervous System Involvement. ACS Chem Neurosci. 2020;11:1204–5. 10.1021/acschemneuro.0c00181 - DOI - PubMed
    1. McIntosh K. COVID-19: Clinical features. Available from: http://www.uptodate.co. Accessed September 20th 2021.